4SC AG Logo

4SC AG

Developing small-molecule epigenetic drugs for high-need cancer indications.

VSC | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C40
LEI:
391200QOKN7LGVP0RQ86
Country:
Germany
Address:
Fraunhoferstr. 22, 82152 Planegg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

4SC AG is a clinical-stage biopharmaceutical company specializing in the development of small-molecule drugs for cancer treatment. The company focuses on oncology indications with high unmet medical needs. Its core research and development strategy targets key epigenetic mechanisms involved in cancer development and progression, with a particular emphasis on histone deacetylase (HDAC) inhibitors. The company's product pipeline comprises drug programs in various stages of clinical development, aiming to offer patients more effective and better-tolerated therapeutic options to improve their quality of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2025-01-16 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
German 6.4 KB
2024-08-08 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 101.6 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2023-11-27 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.3 KB
2023-08-10 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
German 100.3 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.3 KB
2022-12-20 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2022-11-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 174.5 KB
2021-12-01 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2021 bis zum 31.12.2021
German 6.4 KB
2021-12-01 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 6.4 KB
2021-05-26 00:00
Annual Report
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-02-04 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2021 bis zum 30.06.2021
German 6.4 KB
2021-02-04 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2020 bis zum 31.12.2020
German 6.4 KB
2020-05-08 00:00
Business and Financial Review
Q1 statement / Q1 financial report 2020
English 489.3 KB

Automate Your Workflow. Get a real-time feed of all 4SC AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 4SC AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 4SC AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460

Talk to a Data Expert

Have a question? We'll get back to you promptly.